| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | CEO and President | See Remarks
1 company
Mahadevia Ankit is a Director at SPRO. Recent filings cover 0 purchases and 28 sales. Those positions are worth an estimated $1.4M at current prices.
Our model assigns Mahadevia Ankit a middling insider score of 58/100, based on 7 past trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of +0.1%.
Mahadevia Ankit's largest disclosed position is in SPRO as Director, worth about $1.4M. The recent filings there lean toward selling, a net 224,500 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 28, 2025 | SPRO Spero Therapeutics, Inc. | Director | Sell | 6,572 | $1.97 | $12,946.84 | -0.9% | +16.5% | -40.0% | |
| Feb 5, 2025 | SPRO Spero Therapeutics, Inc. | Director | Sell | 69,219 | $0.78 | $53,990.82 | -9.1% | -32.7% | +162.3% | |
| Aug 27, 2024 | SPRO Spero Therapeutics, Inc. | Director | Sell | 5,912 | $1.35 | $7,981.20 | -0.8% | -16.7% | +43.5% | |
| Feb 2, 2024 | SPRO Spero Therapeutics, Inc. | Director | Sell | 63,795 | $1.37 | $87,399.15 | -7.9% | +10.7% | -41.1% | |
| Aug 28, 2023 | SPRO Spero Therapeutics, Inc. | Director | Sell | 9,040 | $1.26 | $11,390.40 | -1.1% | -7.1% | +9.5% | |
| Feb 3, 2023 | SPRO Spero Therapeutics, Inc. | CEO and President | Sell | 12,286 | $1.81 | $22,237.66 | -1.5% | -1.1% | -23.4% | |
| Dec 27, 2021 | SPRO Spero Therapeutics, Inc. | CEO and President | Sale+OE | 8,000 | $14.58 | $116,666.40 | -5.3% | -45.1% | -89.2% | |
| Nov 4, 2020 | SPRO Spero Therapeutics, Inc. | CEO and President | Sale+OE | 9,507 | $14.39 | $136,824.74 | -12.6% | - | - | |
| Oct 23, 2020 | SPRO Spero Therapeutics, Inc. | CEO and President | Sale+OE | 20 | $14.25 | $285.00 | - | - | - | |
| Oct 14, 2020 | SPRO Spero Therapeutics, Inc. | CEO and President | Sale+OE | 14,472 | $14.28 | $206,708.73 | -18.0% | - | - |